Braude M, Ratnam DT, Marsh L, Abasszade JH, Dev AT. Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports. World J Gastrointest Pharmacol Ther 2023; 14(4): 33-38 [PMID: 37484883 DOI: 10.4292/wjgpt.v14.i4.33]
Corresponding Author of This Article
Michael Braude, MBBS, PhD, FRACP, Department of Gastroenterology and Hepatology, Monash Health, 246 Clayton Road, Clayton 3168, VIC, Australia. mrh.braude@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Jul 5, 2023; 14(4): 33-38 Published online Jul 5, 2023. doi: 10.4292/wjgpt.v14.i4.33
Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports
Michael Braude, Dilip T Ratnam, Louise Marsh, Joshua H Abasszade, Anouk T Dev
Michael Braude, Dilip T Ratnam, Joshua H Abasszade, Anouk T Dev, Department of Gastroenterology and Hepatology, Monash Health, Clayton 3168, VIC, Australia
Louise Marsh, General Practice, Margaret River Medical Centre, Margaret River 6285, Australia
Author contributions: Braude M designed and drafted the manuscript; Ratnam DT and Dev AT provided hypothesis generation, patient care and hepatology expertise; Marsh L provided patient data and clinical support; Braude M and Abasszade JH edited the manuscript; and all authors contributed to drafting of the manuscript.
Informed consent statement: Informed consent was obtained from each patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Braude, MBBS, PhD, FRACP, Department of Gastroenterology and Hepatology, Monash Health, 246 Clayton Road, Clayton 3168, VIC, Australia. mrh.braude@gmail.com
Received: April 2, 2023 Peer-review started: April 2, 2023 First decision: April 20, 2023 Revised: May 26, 2023 Accepted: June 19, 2023 Article in press: June 19, 2023 Published online: July 5, 2023 Processing time: 92 Days and 20.6 Hours
Core Tip
Core Tip: Current hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies are not recommended in patients who are co-prescribed carbamazepine. For glecaprevir-pibrentasvir, this is primarily due to carbamazepine’s potent induction of cytochrome P450 3A4 and P-glycoprotein which reduces DAA plasma concentration and may therefore lead to virological failure. Despite theoretical reduction in DAA bioavailability, glecaprevir-pibrentasvir, prescribed over 12-wk, may be an effective treatment for non-cirrhotic patients with HCV who are co-prescribed carbamazepine. Glecaprevir-pibrentasvir should be considered for management of HCV in non-cirrhotic patients who are unable to substitute carbamazepine therapy. Further pharmacokinetic and potency data are required, in addition to further data in patients with cirrhosis.
